• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SUD
Click for more information
0.00% 4.2¢

SUDA PHARMACEUTICALS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SUD Initial Director's Interest Notice28/03/19
SUD SUDA Appoints David Simmonds To The Board27/03/19
SUD Program Update Anagrelide15/03/19
SUD Top 20 securityholders01/03/19
SUD Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
SUD Program Update Anagrelide21/02/19
SUD SUDA Continues To Expand Patent Coverage18/02/19
SUD Appendix 3B04/02/19
SUD Appendix 4C AmendedPRICE SENSITIVE04/02/19
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
SUD SUDA Signs Agreement With Mitsubishi TanabePRICE SENSITIVE19/12/18
SUD ZLD: ZLD to Invest in Development of Oral Spray FormulationsPRICE SENSITIVE06/12/18
SUD SUDA Enters Agreement To Develop Cannabinoid SprayPRICE SENSITIVE06/12/18
SUD Results of Meeting15/11/18
SUD AGM Presentation15/11/18
SUD SUDA Receives R&D Tax Incentive RefundPRICE SENSITIVE15/11/18
SUD ZolpiMist Market UpdatePRICE SENSITIVE13/11/18
SUD Anagrelide Paper By SUDA Scientific Board Member12/11/18
SUD Strides Press Release09/11/18
SUD Boardroom Radio Broadcast08/11/18
SUD SUDA Signs Agreement For SUD-001H For US MarketPRICE SENSITIVE08/11/18
SUD Trading HaltPRICE SENSITIVE07/11/18
SUD Appendix 4C, Market Update and Top 20PRICE SENSITIVE29/10/18
SUD Reinstatement to Official QuotationPRICE SENSITIVE17/10/18
SUD Response to ASX Price QueryPRICE SENSITIVE17/10/18
SUD Suspension from Official QuotationPRICE SENSITIVE17/10/18
SUD Pause in TradingPRICE SENSITIVE17/10/18
SUD Notice of Annual General Meeting/Proxy Form12/10/18
SUD SUDA Appoints Business Development VP In The USA11/10/18
SUD Annual Report to shareholders28/09/18
SUD Appendix 4G and Corporate Governance Statement28/09/18
SUD Market UpdatePRICE SENSITIVE12/09/18
SUD Request for Trading HaltPRICE SENSITIVE11/09/18
SUD Trading HaltPRICE SENSITIVE11/09/18
SUD Pause in TradingPRICE SENSITIVE11/09/18
SUD SUDA Accredited As An Australian Trusted Trader10/09/18
SUD SUDA Expands Scientific Advisory Board For Anagrelide06/09/18
SUD Preliminary Final ReportPRICE SENSITIVE31/08/18
SUD Investor Presentation28/08/18
SUD SUDA Expands Patent Coverage For Sildenafil Sprays22/08/18
SUD SUDA Achieves TGA GMP LicencePRICE SENSITIVE21/08/18
SUD Top 20 securityholders14/08/18
SUD Change of Directors' Interest Notice03/08/18
SUD Rights Issue and Placement Completed and Appendix 3B02/08/18
SUD Rights Issue Closes Significantly OversubscribedPRICE SENSITIVE31/07/18
SUD Supplementary ProspectusPRICE SENSITIVE31/07/18
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
SUD Change of Director's Interest Notice31/07/18
SUD David Phillips To Lead Business Development25/07/18
SUD Corporate Presentation17/07/18
SUD ASX Waiver To Grant Secured Convertible Notes16/07/18
SUD Business Development UpdatePRICE SENSITIVE16/07/18
SUD Anagrelide UpdatePRICE SENSITIVE12/07/18
SUD Letter to Ineligible Shareholders02/07/18
SUD Letter to Eligible Shareholders02/07/18
SUD Prospectus for a Renounceable Pro Rata OfferPRICE SENSITIVE02/07/18
SUD Appendix 3B02/07/18
SUD Settlement with HC Berlin Pharma and Rights IssuePRICE SENSITIVE02/07/18
SUD Trading HaltPRICE SENSITIVE28/06/18
SUD Shareholder UpdatePRICE SENSITIVE21/06/18
SUD SUDA Expands Patent Coverage For SildenafilPRICE SENSITIVE18/06/18
SUD SUDA announces update on ZolpiMist in USA and CanadaPRICE SENSITIVE15/06/18
SUD SUDA Establishes Scientific Advisory Board15/05/18
SUD Shareholder update09/05/18
SUD SUDA expands dialogue with World Health OrganisationPRICE SENSITIVE07/05/18
SUD HC Berlin Pharma Update04/05/18
SUD HC Berlin Pharma UpdatePRICE SENSITIVE01/05/18
SUD Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
SUD Final Director's Interest Notice11/04/18
SUD SUDA Announces Resignation of Michael Stewart10/04/18
SUD Initial Director's Interest Notice09/04/18
SUD SUDA Appoints David Phillips To The Board09/04/18
SUD Appendix 3B05/04/18
SUD HC Berlin Pharma UpdatePRICE SENSITIVE29/03/18
SUD SUDA Completes Divestment of SubsidiaryPRICE SENSITIVE08/03/18
SUD Half Yearly Report and AccountsPRICE SENSITIVE28/02/18
SUD Divestment Of Non-Core SubsidiaryPRICE SENSITIVE27/02/18
SUD New Analyst ReportPRICE SENSITIVE16/02/18
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
SUD SUDA Completes Acquisition Of Anti-Cancer AgentPRICE SENSITIVE24/01/18
SUD New Data Supporting Use Of Anagrelide To Treat Cancer13/12/17
SUD Amended Appendix 3B12/12/17
SUD Change of Directors' Interest Notice12/12/17
SUD Appendix 3B12/12/17
SUD SUDA's Licensee Submits Marketing ApplicationPRICE SENSITIVE06/12/17
SUD Change of Director's Interest Notice30/11/17
SUD SUDA Receives R&D Tax Incentive RefundPRICE SENSITIVE30/11/17
SUD Change of Company Name29/11/17
SUD SUDA Appoints David Phillips As Advisor To The Board28/11/17
SUD Results of Meeting28/11/17
SUD AGM Presentation28/11/17
SUD SUDA Acquires Novel Oro-Mucosal Anti-Cancer AgentPRICE SENSITIVE28/11/17
SUD Change of Director's Interest Notice24/11/17
SUD Change of Director's Interest Notice17/11/17
SUD Change of Director's Interest Notice10/11/17
SUD SUDA Announces New Media Article09/11/17
SUD Change of Director's Interest Notice03/11/17
SUD Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
SUD Notice of Annual General Meeting/Proxy Form30/10/17
SUD Appendix 3B06/10/17
SUD Initial Director's Interest Notice
28/03/19
SUD SUDA Appoints David Simmonds To The Board
27/03/19
SUD Program Update Anagrelide
15/03/19
SUD Top 20 securityholders
01/03/19
SUD Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
SUD Program Update Anagrelide
21/02/19
SUD SUDA Continues To Expand Patent Coverage
18/02/19
SUD Appendix 3B
04/02/19
SUD Appendix 4C Amended
04/02/19PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
SUD SUDA Signs Agreement With Mitsubishi Tanabe
19/12/18PRICE SENSITIVE
SUD ZLD: ZLD to Invest in Development of Oral Spray Formulations
06/12/18PRICE SENSITIVE
SUD SUDA Enters Agreement To Develop Cannabinoid Spray
06/12/18PRICE SENSITIVE
SUD Results of Meeting
15/11/18
SUD AGM Presentation
15/11/18
SUD SUDA Receives R&D Tax Incentive Refund
15/11/18PRICE SENSITIVE
SUD ZolpiMist Market Update
13/11/18PRICE SENSITIVE
SUD Anagrelide Paper By SUDA Scientific Board Member
12/11/18
SUD Strides Press Release
09/11/18
SUD Boardroom Radio Broadcast
08/11/18
SUD SUDA Signs Agreement For SUD-001H For US Market
08/11/18PRICE SENSITIVE
SUD Trading Halt
07/11/18PRICE SENSITIVE
SUD Appendix 4C, Market Update and Top 20
29/10/18PRICE SENSITIVE
SUD Reinstatement to Official Quotation
17/10/18PRICE SENSITIVE
SUD Response to ASX Price Query
17/10/18PRICE SENSITIVE
SUD Suspension from Official Quotation
17/10/18PRICE SENSITIVE
SUD Pause in Trading
17/10/18PRICE SENSITIVE
SUD Notice of Annual General Meeting/Proxy Form
12/10/18
SUD SUDA Appoints Business Development VP In The USA
11/10/18
SUD Annual Report to shareholders
28/09/18
SUD Appendix 4G and Corporate Governance Statement
28/09/18
SUD Market Update
12/09/18PRICE SENSITIVE
SUD Request for Trading Halt
11/09/18PRICE SENSITIVE
SUD Trading Halt
11/09/18PRICE SENSITIVE
SUD Pause in Trading
11/09/18PRICE SENSITIVE
SUD SUDA Accredited As An Australian Trusted Trader
10/09/18
SUD SUDA Expands Scientific Advisory Board For Anagrelide
06/09/18
SUD Preliminary Final Report
31/08/18PRICE SENSITIVE
SUD Investor Presentation
28/08/18
SUD SUDA Expands Patent Coverage For Sildenafil Sprays
22/08/18
SUD SUDA Achieves TGA GMP Licence
21/08/18PRICE SENSITIVE
SUD Top 20 securityholders
14/08/18
SUD Change of Directors' Interest Notice
03/08/18
SUD Rights Issue and Placement Completed and Appendix 3B
02/08/18
SUD Rights Issue Closes Significantly Oversubscribed
31/07/18PRICE SENSITIVE
SUD Supplementary Prospectus
31/07/18PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
SUD Change of Director's Interest Notice
31/07/18
SUD David Phillips To Lead Business Development
25/07/18
SUD Corporate Presentation
17/07/18
SUD ASX Waiver To Grant Secured Convertible Notes
16/07/18
SUD Business Development Update
16/07/18PRICE SENSITIVE
SUD Anagrelide Update
12/07/18PRICE SENSITIVE
SUD Letter to Ineligible Shareholders
02/07/18
SUD Letter to Eligible Shareholders
02/07/18
SUD Prospectus for a Renounceable Pro Rata Offer
02/07/18PRICE SENSITIVE
SUD Appendix 3B
02/07/18
SUD Settlement with HC Berlin Pharma and Rights Issue
02/07/18PRICE SENSITIVE
SUD Trading Halt
28/06/18PRICE SENSITIVE
SUD Shareholder Update
21/06/18PRICE SENSITIVE
SUD SUDA Expands Patent Coverage For Sildenafil
18/06/18PRICE SENSITIVE
SUD SUDA announces update on ZolpiMist in USA and Canada
15/06/18PRICE SENSITIVE
SUD SUDA Establishes Scientific Advisory Board
15/05/18
SUD Shareholder update
09/05/18
SUD SUDA expands dialogue with World Health Organisation
07/05/18PRICE SENSITIVE
SUD HC Berlin Pharma Update
04/05/18
SUD HC Berlin Pharma Update
01/05/18PRICE SENSITIVE
SUD Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
SUD Final Director's Interest Notice
11/04/18
SUD SUDA Announces Resignation of Michael Stewart
10/04/18
SUD Initial Director's Interest Notice
09/04/18
SUD SUDA Appoints David Phillips To The Board
09/04/18
SUD Appendix 3B
05/04/18
SUD HC Berlin Pharma Update
29/03/18PRICE SENSITIVE
SUD SUDA Completes Divestment of Subsidiary
08/03/18PRICE SENSITIVE
SUD Half Yearly Report and Accounts
28/02/18PRICE SENSITIVE
SUD Divestment Of Non-Core Subsidiary
27/02/18PRICE SENSITIVE
SUD New Analyst Report
16/02/18PRICE SENSITIVE
SUD Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
SUD SUDA Completes Acquisition Of Anti-Cancer Agent
24/01/18PRICE SENSITIVE
SUD New Data Supporting Use Of Anagrelide To Treat Cancer
13/12/17
SUD Amended Appendix 3B
12/12/17
SUD Change of Directors' Interest Notice
12/12/17
SUD Appendix 3B
12/12/17
SUD SUDA's Licensee Submits Marketing Application
06/12/17PRICE SENSITIVE
SUD Change of Director's Interest Notice
30/11/17
SUD SUDA Receives R&D Tax Incentive Refund
30/11/17PRICE SENSITIVE
SUD Change of Company Name
29/11/17
SUD SUDA Appoints David Phillips As Advisor To The Board
28/11/17
SUD Results of Meeting
28/11/17
SUD AGM Presentation
28/11/17
SUD SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
28/11/17PRICE SENSITIVE
SUD Change of Director's Interest Notice
24/11/17
SUD Change of Director's Interest Notice
17/11/17
SUD Change of Director's Interest Notice
10/11/17
SUD SUDA Announces New Media Article
09/11/17
SUD Change of Director's Interest Notice
03/11/17
SUD Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
SUD Notice of Annual General Meeting/Proxy Form
30/10/17
SUD Appendix 3B
06/10/17
refresh Created with Sketch. REFRESH
 

Top Stories

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.